Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, leading to loss of muscle control and eventually paralysis.
ALS Treatment: Masitinib with Riluzole
We are studying whether adding masitinib to Riluzole helps improve outcomes for people with Amyotrophic Lateral Sclerosis. This trial will assess its safety and effectiveness compared to a placebo.
6-12 months16-20 visitsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesOralInternal MedicineNeurology
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 18 and 80 years old?
- Have you been diagnosed with ALS (amyotrophic lateral sclerosis)?
- Are you currently pregnant or breastfeeding?
- Are you taking Riluzole (also known as Rilutek) daily?
- Do you have any significant neurological or psychiatric conditions that might interfere with the trial?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Masitinib
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Aarhus University Hospital
Neurology
Århus, Denmark
Bispebjerg Hospital
Neurology
Frederiksberg, Denmark
Centre Hospitalier Universitaire D'Angers
Neurology
Angers, France
Sponsor: Ab Science
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.